Labiotech.eu

News and Trends 29 Aug 2022

Vilya emerges to target disease biology

VILYA, Inc. (Vilya), a biotech company aiming to create a new class of medicines to precisely target disease biology, launched today. Vilya is co-founded by scientists from the Institute of Protein Design (IPD) led by David Baker, and ARCH Venture Partners. The company’s platform, powered by advanced machine learning, taps into uncharted chemical space to […]

August 29, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 29 Aug 2022

Grid Biosciences signs agreement with NIH for Epstein-Barr virus vaccine

Grid Biosciences has signed a license agreement for the development of a vaccine against Epstein-Barr virus (EBV) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The agreement includes access to NIH’s patent rights in EBV envelope proteins that the virus uses to gain entry into […]

August 29, 2022 - 2 minutesmins - By Jim Cornall

covid-19 vaccine emergency use authorization

News and Trends 29 Aug 2022

AIVITA Biomedical announces publication of trial results of its COVID-19 vaccine

Safety and efficacy results from phase 1 and 2 clinical trials looking at a Covid-19 vaccine made at point-of-care by third party personnel have been published. AIVITA Biomedical Inc., a biotech specializing in cell applications, made the announcement today (August 29). The results were published in the article in the journal Human Vaccines & Immunotherapeutics. […]

August 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Aug 2022

PharmAla Biotech files patent applications for MDMA analogs

Canadian company PharmAla Biotech has filed a key patent cooperation treaty (PCT) application, containing six novel chemical entities (NCEs). The application claims priority to, and benefit of a United States provisional patent application filed August 20, 2021. The PCT application disclosed novel compositions of MDMA and analogs that may be used to alleviate the known […]

August 29, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Aug 2022

Marketing authorization granted for treatment of serious retinal diseases

The European Commission has granted marketing authorization to Ranivisio, a treatment for several serious retinal diseases. Polpharma Biologics Group BV, Formycon AG and their Swiss joint venture, Bioeq AG, announced the news today (August 29) that the authorization was granted to Ranivisio, which is a biosimilar to Lucentis, a ranibizumab injection. Positive opinion: CHMP The […]

August 29, 2022 - 3 minutesmins - By Liza Laws

Interview 29 Aug 2022

Making a success out of technology transfer at UCLB

Having a good relationship with the technology transfer office at your university can be key to creating a successful startup. Anne Lane, CEO of University College London’s (UCL’s) commercialization company UCLB, discusses recent successes and shares insights on how to advance new innovations. Anne Lane began her career as a scientist, completing a PhD at […]

August 29, 2022 - 13 minutesmins - By Helen Albert

News and Trends 29 Aug 2022

Strategic collaboration announced in China to accelerate the development of bacterial drugs

A strategic cooperation between Porton Advanced Solutions and Suzhou Royaltech Med Co., Ltd was announced today (August 29). The companies say the collaboration which was agreed earlier in the month (August 19) is set to integrate the resources and capabilities of both parties. The say it will jointly promote the establishment of microbial vectors used […]

August 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Aug 2022

Malaysian Genomics and Ajlan to explore MENA biopharma opportunities

Malaysian Genomics Resource Centre Berhad, a genomics and biopharmaceutical company, has signed a memorandum of understanding (MoU) to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company. Ajlan, based in Riyadh, Saudi Arabia, is part of a multinational conglomerate established in 1979 with extensive global private […]

August 29, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 29 Aug 2022

Sanyou and KangaBio to collaborate on antibody drug development and innovation

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Shanghai KangaBio Co., Ltd. have reached an antibody drug licensing agreement. The subject of the agreement is a monoclonal antibody drug developed by Sanyou Biopharmaceuticals, which grants KangaBio an exclusive license to exploit the antibody for research, development, manufacturing and commercialization of immunotherapy products. Previously, KangaBio and Sanyou Biopharmaceuticals […]

August 29, 2022 - 3 minutesmins - By Jim Cornall

Covid vaccine lawsuit: Moderna vs Pfizer

News and Trends 26 Aug 2022

Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology”

Moderna is today (August 26) filing patent infringement lawsuits against Pfizer and its partner BioNTech in both the U.S and Germany. The mRNA-focused biotech claims the companies’ Covid-19 vaccine Comirnaty infringes patents it led between 2010 and 2016 covering Moderna’s foundational mRNA technology which the company says was critical to the development of its own […]

August 26, 2022 - 4 minutesmins - By Liza Laws

Startup Scout 26 Aug 2022

Epic Bio makes gene therapies by editing the epigenome

CRISPR-Cas9 genome editing has changed the game for gene therapy, but carries safety risks when cutting DNA. The new U.S. firm Epic Bio aims to reduce these risks by targeting epigenetic controls on gene expression. The development of the genome-editing tool CRISPR-Cas9 caused a paradigm shift in the biotech industry because it made it easier […]

August 26, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 26 Aug 2022

Swedish researchers developing new treatment for chronic hepatitis B and D infections

A new immunological treatment against hepatitis B and D viruses, both of which can cause liver cancer, shows promising results in animal models. Results from the treatment, which is being developed by researchers at Karolinska Institutet in Sweden, have been published in the journal Gut. Chronic infections of the hepatitis B virus (HBV) and hepatitis […]

August 26, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Vilya emerges to target disease biology

Grid Biosciences signs agreement with NIH for Epstein-Barr virus vaccine

AIVITA Biomedical announces publication of trial results of its COVID-19 vaccine

PharmAla Biotech files patent applications for MDMA analogs

Marketing authorization granted for treatment of serious retinal diseases

Making a success out of technology transfer at UCLB

Strategic collaboration announced in China to accelerate the development of bacterial drugs

Malaysian Genomics and Ajlan to explore MENA biopharma opportunities

Sanyou and KangaBio to collaborate on antibody drug development and innovation

Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology”

Epic Bio makes gene therapies by editing the epigenome

Swedish researchers developing new treatment for chronic hepatitis B and D infections

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!